文献速递心律失常冠心病

根据NT-proBNP水平分析房颤筛查效果:LOOP随机试验的二次分析

Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
PubMed 文献 · Circulation · 2023-04-15

本研究基于LOOP随机试验的5819例≥70岁且有额外卒中危险因素的无房颤受试者,按基线NT-proBNP水平分析植入式循环记录仪(ILR)筛查房颤的疗效。结果发现,NT-proBNP高于中位数者接受ILR筛查可显著降低卒中/系统性栓塞和卒中/系统性栓塞/心血管死亡风险,而低于中位数者无此获益,交互作用显著。

要点

  • NT-proBNP高于中位数者接受ILR筛查可降低卒中/系统性栓塞风险(HR 0.60)。
  • NT-proBNP低于中位数者接受ILR筛查未见卒中风险降低。
  • NT-proBNP水平可能用于筛选房颤筛查的获益人群,但需进一步研究验证。

核心结论

  • 在老年且有额外卒中危险因素的人群中,ILR筛查房颤仅在NT-proBNP较高者中与卒中风险显著降低相关,较低者无显著获益。

研究设计与样本

  • LOOP试验的事后二次分析,纳入5819例基线有NT-proBNP测量的无房颤受试者(占试验人群96.9%),随机1:3接受ILR筛查(检测≥6分钟房颤即启动抗凝)或常规 care。

主要发现

  • NT-proBNP高于中位数与ILR组(HR 1.84,95%CI 1.51-2.25)和对照组(HR 2.79,95%CI 2.30-3.40)房颤诊断风险增加相关。
  • NT-proBNP高于中位数者临床事件风险更高:卒中/系统性栓塞HR 1.21(95%CI 0.96-1.54),卒中/系统性栓塞/心血管死亡HR 1.60(95%CI 1.32-1.95),全因死亡HR 1.91(95%CI 1.61-2.26)。
  • 与常规 care 相比,ILR筛查在NT-proBNP高于中位数者中显著降低卒中/系统性栓塞(HR 0.60,95%CI 0.40-0.90)和卒中/系统性栓塞/心血管死亡(HR 0.70,95%CI 0.53-0.94),低于中位数者无显著降低(交互作用P=0.029和0.045)。
  • 两个NT-proBNP亚组中ILR与对照的全因死亡风险降低均无显著差异(交互作用P=0.68)。

关键数值与推荐

  • NT-proBNP中位数为15 pmol/L(四分位距9-28 pmol/L),对应125 pg/mL(四分位距76-233 pg/mL)。
  • ILR筛查在NT-proBNP高于中位数者中卒中/系统性栓塞HR 0.60(95%CI 0.40-0.90),卒中/系统性栓塞/心血管死亡HR 0.70(95%CI 0.53-0.94)。

临床怎么用

  • NT-proBNP可能作为选择房颤筛查获益人群的参考指标,但当前结果仅属假设生成,临床实施前需进一步研究。

局限性

  • 为事后二次分析,结果应视为假设生成,需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Research suggests NT-proBNP (N-terminal pro-B-type natriuretic peptide) to be a strong predictor of incident atrial fibrillation (AF) and stroke. However, its utility in AF screening remains unknown. The aim of this study was to investigate NT-proBNP as a potential marker for screening efficacy with respect to AF yield and stroke prevention. METHODS: In the LOOP Study (Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-Risk Individuals), 6004 AF-naïve individuals at least 70 years old and with additional stroke risk factors were randomized 1:3 to either screening with an implantable loop recorder (ILR) and initiation of anticoagulation upon detection of AF episodes lasting ≥6 minutes or usual care (control). This post hoc analysis included study participants with available NT-proBNP measurement at baseline. RESULTS: A total of 5819 participants (96.9% of the trial population) were included. The mean age was 74.7 years (SD, 4.1 years) and 47.5% were female. The median NT-proBNP level was 15 pmol/L (interquartile range, 9-28 pmol/L) corresponding to 125 pg/mL (interquartile range, 76-233 pg/mL). NT-proBNP above median was associated with an increased risk of AF diagnosis both in the ILR group (hazard ratio, 1.84 [95% CI, 1.51-2.25]) and the control group (hazard ratio, 2.79 [95% CI, 2.30-3.40]). Participants with NT-proBNP above the median were also at higher risk of clinical events compared with those having lower levels (hazard ratio, 1.21 [95% CI, 0.96-1.54] for stroke or systemic embolism [SE], 1.60 [95% CI, 1.32-1.95] for stroke/SE/cardiovascular death, and 1.91 [95% CI, 1.61-2.26] for all-cause death). Compared with usual care, ILR screening was associated with significant reductions in stroke/SE and stroke/SE/cardiovascular death among participants with NT-proBNP above median (hazard ratio, 0.60 [95% CI, 0.40-0.90] and 0.70 [95% CI, 0.53-0.94], respectively) but not among those with lower levels (Pinteraction=0.029 for stroke/SE and 0.045 for stroke/SE/cardiovascular death). No risk reduction in all-cause death was observed in either NT-proBNP subgroup for ILR versus control (Pinteraction=0.68). Analyzing NT-proBNP as a continuous variable yielded similar findings. CONCLUSIONS: In an older population with additional stroke risk factors, ILR screening for AF was associated with a significant reduction in stroke risk among individuals with higher NT-proBNP levels but not among those with lower levels. These findings should be considered hypothesis generating and warrant further study before clinical implementation. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02036450.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Xing, Diederichsen, Højberg, et al. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study. Circulation. 2023. PMID: 37061802. doi:10.1161/CIRCULATIONAHA.123.064361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。